BPI-9016
As of the edition of 20 October 2026, BPI-9016 is a drug: of no established status; acts on AXL and MET.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Status not established
- Kind
- Unknown
- Registered trials
- 2, 0 stopped early
- Disease areas
- Cancer; Lungs and airways
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 2 | 1 | 0 | 0 |
| All trials | 2 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Betta Pharmaceuticals | Lead sponsor of trials | 2015 to now |